XML 37 R26.htm IDEA: XBRL DOCUMENT
v3.19.2

Collaborative Arrangements (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2019
Collaborative Arrangements [Abstract] |
Collaboration Arrangements | Summarized financial information related to this collaboration is as follows:
| Three Months Ended June 30, |  | Six Months Ended June 30,
($ in millions) | 2019 |  | 2018 |  | 2019 |  | 2018
Alliance revenue | $ | 97 |  |  | $ | 35 |  |  | $ | 171 |  |  | $ | 35 |
Cost of sales (1) | 23 |  |  | 1 |  |  | 74 |  |  | 1 |
Selling, general and administrative | 19 |  |  | 2 |  |  | 38 |  |  | 2 |
Research and development (2) | 62 |  |  | 36 |  |  | 109 |  |  | 1,436 |
($ in millions) |  |  |  |  | June 30, 2019 |  | December 31, 2018
Receivables from Eisai included in Other current assets |  |  |  |  | $ | 98 |  |  | $ | 71 |
Payables to Eisai included in Accrued and other current liabilities (3) |  |  |  |  | 709 |  |  | 375 |
Payables to Eisai included in Other Noncurrent Liabilities (3) |  |  |  |  | 125 |  |  | 543 |
(1) Represents amortization of capitalized milestone payments. (2) Amount for the first six months of 2018 includes the upfront payment and future option payments. (3) Includes accrued milestone and option payments. Summarized financial information related to this collaboration is as follows:
| Three Months Ended June 30, |  | Six Months Ended June 30,
($ in millions) | 2019 |  | 2018 |  | 2019 |  | 2018
Alliance revenue | $ | 111 |  |  | $ | 44 |  |  | $ | 190 |  |  | $ | 76 |
Cost of sales (1) | 73 |  |  | 24 |  |  | 92 |  |  | 36 |
Selling, general and administrative | 33 |  |  | 9 |  |  | 59 |  |  | 16 |
Research and development | 33 |  |  | 42 |  |  | 78 |  |  | 71 |
($ in millions) |  |  |  |  | June 30, 2019 |  | December 31, 2018
Receivables from AstraZeneca included in Other current assets |  |  |  |  | $ | 105 |  |  | $ | 52 |
Payables to AstraZeneca included in Accrued and other current liabilities (2) |  |  |  |  | 605 |  |  | 405 |
Payables to AstraZeneca included in Other Noncurrent Liabilities (3) |  |  |  |  | 300 |  |  | 250 |
(1) Represents amortization of capitalized milestone payments. (2) Includes accrued milestone and license option payments. Summarized financial information related to this collaboration is as follows:
| Three Months Ended June 30, |  | Six Months Ended June 30,
($ in millions) | 2019 |  | 2018 |  | 2019 |  | 2018
Net product sales recorded by Merck | $ | 53 |  |  | $ | 47 |  |  | $ | 100 |  |  | $ | 90 |
Merck’s profit share from sales in Bayer’s marketing territories | 51 |  |  | 28 |  |  | 94 |  |  | 53 |
Total sales | 104 |  |  | 75 |  |  | 194 |  |  | 143 |
Cost of sales (1) | 29 |  |  | 132 |  |  | 58 |  |  | 159 |
Selling, general and administrative | 11 |  |  | 10 |  |  | 20 |  |  | 17 |
Research and development | 32 |  |  | 28 |  |  | 62 |  |  | 56 |
($ in millions) |  |  |  |  | June 30, 2019 |  | December 31, 2018
Receivables from Bayer included in Other current assets |  |  |  |  | $ | 41 |  |  | $ | 32 |
Payables to Bayer included in Other Noncurrent Liabilities (2) |  |  |  |  | 375 |  |  | 375 |
(1) Includes amortization of intangible assets. (2) Represents accrued milestone payment.

X
- Definition Collaborative Arrangements [Abstract] + References No definition available. + Details
Name: | mrk_CollaborativeArrangementsAbstract
Namespace Prefix: | mrk_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration